Shilpa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHILPA, and when can generic versions of SHILPA drugs launch?
SHILPA has thirteen approved drugs.
There are five US patents protecting SHILPA drugs. There are two tentative approvals on SHILPA drugs.
There are fifty-four patent family members on SHILPA drugs in twenty-six countries and forty-eight supplementary protection certificates in sixteen countries.
Summary for Shilpa
| International Patents: | 54 |
| US Patents: | 5 |
| Tradenames: | 11 |
| Ingredients: | 11 |
| NDAs: | 13 |
| Patent Litigation for Shilpa: | See patent lawsuits for Shilpa |
Drugs and US Patents for Shilpa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa | CAPECITABINE | capecitabine | TABLET;ORAL | 207456-001 | Dec 12, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-003 | Dec 22, 2015 | AP | RX | Yes | Yes | 10,842,770 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-002 | Dec 22, 2015 | AP | RX | Yes | Yes | 10,842,770 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Shilpa | ERLOTINIB HYDROCHLORIDE | erlotinib hydrochloride | TABLET;ORAL | 211960-001 | Nov 5, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 8,940,786 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Shilpa Medicare | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207518-001 | Sep 29, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 210327-002 | May 16, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shilpa Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| India | 2661DEN2015 | ⤷ Try a Trial |
| Singapore | 11201502352W | ⤷ Try a Trial |
| Mexico | 341082 | ⤷ Try a Trial |
| Japan | 2015534558 | ⤷ Try a Trial |
| Russian Federation | 2015116260 | ⤷ Try a Trial |
| Taiwan | 201526889 | ⤷ Try a Trial |
| China | 109745287 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shilpa Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2962690 | 122019000070 | Germany | ⤷ Try a Trial | PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 20150115 |
| 0432677 | SPC/GB05/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920 |
| 1746976 | LUC00026 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
| 0275821 | SPC/GB01/039 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ZOLEDRONIC ACID OPTIONALLY IN THE FORM OF A SALT THEREOF; NATIONAL REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: CH 55463 20001128 |
| 0432677 | 7/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920 |
| 0137145 | SPC/GB97/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
| 0316704 | 2001C/021 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
